Exotic European therapies may not reach U.S.: the small foreign companies that have developed these therapies balk at the costs of FDA review.(Rheumatology): An article from: Internal Medicine News
Price not available for Germany
You can still browse on Amazon. Try another country above.
Book Details
Author(s)
Bruce Jancin
Publisher
Thomson Gale
ISBN / ASIN
B000EGDOMG
ISBN-13
978B000EGDOM2
Marketplace
Germany 🇩🇪
Ratings & Reviews
No reviews yet — be the first!
No reviews yet.
Description
This digital document is an article from Internal Medicine News, published by Thomson Gale on October 15, 2005. The length of the article is 1483 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Exotic European therapies may not reach U.S.: the small foreign companies that have developed these therapies balk at the costs of FDA review.(Rheumatology)
Author: Bruce Jancin
Publication:Internal Medicine News (Magazine/Journal)
Date: October 15, 2005
Publisher: Thomson Gale
Volume: 38 Issue: 20 Page: 23(1)
Distributed by Thomson Gale
Citation Details
Title: Exotic European therapies may not reach U.S.: the small foreign companies that have developed these therapies balk at the costs of FDA review.(Rheumatology)
Author: Bruce Jancin
Publication:Internal Medicine News (Magazine/Journal)
Date: October 15, 2005
Publisher: Thomson Gale
Volume: 38 Issue: 20 Page: 23(1)
Distributed by Thomson Gale
